Generating AI analysis...
Revenue
$28.37B
++0.73% YoY
EPS (Basic)
$1.03
++83.93% YoY
Evidence Layer
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $28.37B | $28.16B | +0.73% |
Cost of Revenue | $6.62B | $6.68B | -0.82% |
Net Income | $5.88B | $3.16B | +86.22% |
EPS (Basic) | $1.03 | $0.56 | +83.93% |
EPS (Diluted) | $1.03 | $0.55 | +87.27% |
SG&A Expense | $6.45B | $7.21B | -10.62% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $206.09B | $216.19B | -4.67% |
Current Assets | $43.7B | $37.83B | +15.54% |
Total Liabilities | $117.08B | $128.22B | -8.68% |
Current Liabilities | $37.73B | $43.82B | -13.90% |
Stockholders' Equity | $88.69B | $87.7B | +1.13% |
Cash & Equivalents | $1.64B | $1.05B | +55.70% |
Long-Term Debt | $57.5B | $57.51B | -0.01% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.75B | $-691M | +353.69% |
Investing Cash Flow | $7.22B | $6.33B | +14.10% |
Financing Cash Flow | $-8.42B | $-7.39B | -13.98% |
D&A | $3.24B | $3.47B | -6.46% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 20.7% | — | — |
ROE | 6.6% | — | — |
ROA | 2.9% | — | — |
Current Ratio | $1.158 | — | — |
Debt to Equity | $1.32 | — | — |
Other companies in Pharmaceuticals